EA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancer
A planned American cooperative-group trial will test whether the PD-1 and VEGF bispecific antibody ivonescimab beats the current immunotherapies when added to first-line chemotherapy for bile duct and gallbladder cancer, with survival as the endpoint.
Overview
This ECOG-ACRIN randomised phase 2/3 (NCT07765433) compares ivonescimab with gemcitabine and cisplatin against standard-of-care chemo-immunotherapy (gemcitabine and cisplatin with durvalumab or pembrolizumab) in patients with histologically or cytologically confirmed adenocarcinoma of the biliary tract, including intrahepatic and extrahepatic cholangiocarcinoma and gallbladder carcinoma, that is locally advanced or metastatic. The primary endpoint is overall survival; 336 patients are planned, with a start date of January 2027 and primary completion in December 2028. It is the first-line counterpart of the European SEVILLA trial and the first phase 3-scale test of a bispecific checkpoint antibody in biliary cancer against the TOPAZ-1 and KEYNOTE-966 standards.
Similar pages
not linked directly; found by shared links- TrialSEVILLA
Shares Ivonescimab, Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, VEGF / VEGFR.
- TrialPerioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents.
- TrialSafety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents.
- TrialTRAP-BTC
Shares Gemcitabine + cisplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types).
- TrialDurvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab.
- TrialA Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab.
- TrialMP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents.
- TrialEORTC 1607: pembrolizumab with cisplatin and gemcitabine in biliary tract cancer
Shares Gemcitabine + cisplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types).